Cannabis Science Inc. Moves Forward with MEDIWIET Preparing Observational Study in the Netherlands

COLORADO SPRINGS, Colo., May 27, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in the development of cannabis based medicine, is working closely with Mediwiet and its founder, Mr. Wernard Bruining, on the building blocks necessary for the launch of the Clinical Observational Study, as previously announced.

MEDIWIET is by far the largest European organization of patients who use medicinal cannabis-based treatments.

"Over 3000 people have contacted Mediwiet and the numbers are growing," stated Mr. Mario Lap, President of European Operations and Director of Cannabis Science B.V.

Mediwiet patients, unlike most who receive medicinal cannabis distributed by pharmacies or dispensaries in the Netherlands, only use non-smokable, orally taken, cannabis products. The vast majority of Mediwiet patients have never smoked cannabis and have no history of previous recreational use.

The observational study will aim to provide observational data from patients who use cannabis products seeking treatment of pain and a wide range of severe illnesses such as cancer, Alzheimer's disease, Parkinson's disease, epilepsy and multiple sclerosis. The parties are also discussing a potential research project with the Dutch Association of Lyme Disease Patients who have recently started using cannabis-based medication in order to relieve pain and reduce inflammation stimulated by the bacterial infection.

Mr. Wernard Bruining is known as a Cannabis expert throughout the Netherlands. He started the first dispensary in the Netherlands in the 1970s and recently published a book describing patient experiences with the use of cannabis based medicines entitled Helende Hennep, Patienteninterviews (Healing Hemp – Patient Interviews).

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com 
[email protected]
[email protected]
Tel:       +1 888-777-0658

Investment Inquiries
Robert Kane, CFO & Director
[email protected]
Tel:       +1 561-420-4824

SOURCE Cannabis Science, Inc.